Expanded polyglutamine-binding peptoid as a novel therapeutic agent for treatment of Huntington's disease

Chemistry and Biology

Volumn 18, Issue 9, 2011, Pages 1113-1125

  Chen, Xuesong ^a   Wu, Jun ^a   Luo, Yuan ^a   Liang, Xia ^a   Supnet, Charlene ^a   Kim, Mee Whi ^a   Lotz, Gregor P ^b   Yang, Guocheng ^b   Muchowski, Paul J ^b   Kodadek, Thomas ^c   Bezprozvanny, Ilya ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUNTINGTON PROTEIN, MOUSE; NERVE PROTEIN; NEUROPROTECTIVE AGENT; NUCLEAR PROTEIN; PEPTIDE; PEPTOID; POLYGLUTAMINE;

ANIMAL; ARTICLE; CELL CULTURE; CHEMISTRY; CYTOLOGY; DRUG EFFECT; HUNTINGTON CHOREA; MACHADO JOSEPH DISEASE; METABOLISM; MOUSE; NERVE CELL; PROTEIN BINDING;

ANIMALS; CELLS, CULTURED; HUNTINGTON DISEASE; MACHADO-JOSEPH DISEASE; MICE; NERVE TISSUE PROTEINS; NEURONS; NEUROPROTECTIVE AGENTS; NUCLEAR PROTEINS; PEPTIDES; PEPTOIDS; PROTEIN BINDING;

MUS;

EID: 80053158120     PISSN: 10745521     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.chembiol.2011.06.010     Document Type: Article

References (59)

1. P.G. Alluri, M.M. Reddy, K. Bachhawat-Sikder, H.J. Olivos, and T. Kodadek Isolation of protein ligands from large peptoid libraries J. Am. Chem. Soc. 125 2003 13995 14004 (Pubitemid 37420905)
2. P. Alluri, B. Liu, P. Yu, X. Xiao, and T. Kodadek Isolation and characterization of coactivator-binding peptoids from a combinatorial library Mol. Biosyst. 2 2006 568 579 (Pubitemid 44583905)
3. C.L. Benn, T. Sun, G. Sadri-Vakili, K.N. McFarland, D.P. DiRocco, G.J. Yohrling, T.W. Clark, B. Bouzou, and J.H. Cha Huntingtin modulates transcription, occupies gene promoters in vivo, and binds directly to DNA in a polyglutamine-dependent manner J. Neurosci. 28 2008 10720 10733
4. I. Bezprozvanny Calcium signaling and neurodegenerative diseases Trends Mol. Med. 15 2009 89 100
5. R.K. Chaturvedi, and M.F. Beal Mitochondrial approaches for neuroprotection Ann. N Y Acad. Sci. 1147 2008 395 412
6. X. Chen, T.S. Tang, H. Tu, O. Nelson, M. Pook, R. Hammer, N. Nukina, and I. Bezprozvanny Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 3 J. Neurosci. 28 2008 12713 12724
7. V. Chopra, J.H. Fox, G. Lieberman, K. Dorsey, W. Matson, P. Waldmeier, D.E. Housman, A. Kazantsev, A.B. Young, and S. Hersch A small-molecule therapeutic lead for Huntington's disease: preclinical pharmacology and efficacy of C2-8 in the R6/2 transgenic mouse Proc. Natl. Acad. Sci. USA 104 2007 16685 16689 (Pubitemid 350211077)
8. D.W. Colby, Y. Chu, J.P. Cassady, M. Duennwald, H. Zazulak, J.M. Webster, A. Messer, S. Lindquist, V.M. Ingram, and K.D. Wittrup Potent inhibition of huntingtin aggregation and cytotoxicity by a disulfide bond-free single-domain intracellular antibody Proc. Natl. Acad. Sci. USA 101 2004 17616 17621 (Pubitemid 40051935)
9. D.E. Ehrnhoefer, M. Duennwald, P. Markovic, J.L. Wacker, S. Engemann, M. Roark, J. Legleiter, J.L. Marsh, L.M. Thompson, and S. Lindquist Green tea (-)-epigallocatechin-gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models Hum. Mol. Genet. 15 2006 2743 2751 (Pubitemid 44400401)
10. J.F. Gusella, and M.E. MacDonald Molecular genetics: unmasking polyglutamine triggers in neurodegenerative disease Nat. Rev. Neurosci. 1 2000 109 115
11. L. Hamuro, G. Zhang, T.J. Tucker, C. Self, W.J. Strittmatter, and J.R. Burke Optimization of a polyglutamine aggregation inhibitor peptide (QBP1) using a thioflavin T fluorescence assay Assay Drug Dev. Technol. 5 2007 629 636
12. T. Hara, S.R. Durell, M.C. Myers, and D.H. Appella Probing the structural requirements of peptoids that inhibit HDM2-p53 interactions J. Am. Chem. Soc. 128 2006 1995 2004 (Pubitemid 43277340)
13. S.Q. Harper, P.D. Staber, X. He, S.L. Eliason, I.H. Martins, Q. Mao, L. Yang, R.M. Kotin, H.L. Paulson, and B.L. Davidson RNA interference improves motor and neuropathological abnormalities in a Huntington's disease mouse model Proc. Natl. Acad. Sci. USA 102 2005 5820 5825 (Pubitemid 40559643)
14. V. Heiser, S. Engemann, W. Bröcker, I. Dunkel, A. Boeddrich, S. Waelter, E. Nordhoff, R. Lurz, N. Schugardt, and S. Rautenberg Identification of benzothiazoles as potential polyglutamine aggregation inhibitors of Huntington's disease by using an automated filter retardation assay Proc. Natl. Acad. Sci. USA 99 Suppl 4 2002 16400 16406 (Pubitemid 35470985)
15. S.J. Hershberger, S.G. Lee, and J. Chmielewski Scaffolds for blocking protein-protein interactions Curr. Top. Med. Chem. 7 2007 928 942 (Pubitemid 47044745)
16. J. Hu, M. Matsui, K.T. Gagnon, J.C. Schwartz, S. Gabillet, K. Arar, J. Wu, I. Bezprozvanny, and D.R. Corey Allele-specific silencing of mutant huntingtin and ataxin-3 genes by targeting expanded CAG repeats in mRNAs Nat. Biotechnol. 27 2009 478 484
17. A. Khoshnan, J. Ko, and P.H. Patterson Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity Proc. Natl. Acad. Sci. USA 99 2002 1002 1007 (Pubitemid 34106625)
18. M.W. Kim, Y. Chelliah, S.W. Kim, Z. Otwinowski, and I. Bezprozvanny Secondary structure of Huntingtin amino-terminal region Structure 17 2009 1205 1212
19. J. Ko, S. Ou, and P.H. Patterson New anti-huntingtin monoclonal antibodies: implications for huntingtin conformation and its binding proteins Brain Res. Bull. 56 2001 319 329 (Pubitemid 33062356)
20. J.M. Lecerf, T.L. Shirley, Q. Zhu, A. Kazantsev, P. Amersdorfer, D.E. Housman, A. Messer, and J.S. Huston Human single-chain Fv intrabodies counteract in situ huntingtin aggregation in cellular models of Huntington's disease Proc. Natl. Acad. Sci. USA 98 2001 4764 4769 (Pubitemid 32295050)
21. H.S. Lim, C.T. Archer, and T. Kodadek Identification of a peptoid inhibitor of the proteasome 19S regulatory particle J. Am. Chem. Soc. 129 2007 7750 7751 (Pubitemid 46998162)
22. B. Liu, P.G. Alluri, P. Yu, and T. Kodadek A potent transactivation domain mimic with activity in living cells J. Am. Chem. Soc. 127 2005 8254 8255 (Pubitemid 40828122)
23. J. Liu, T.S. Tang, H. Tu, O. Nelson, E. Herndon, D.P. Huynh, S.M. Pulst, and I. Bezprozvanny Deranged calcium signaling and neurodegeneration in spinocerebellar ataxia type 2 J. Neurosci. 29 2009 9148 9162
24. C. Montoliu, M. Humet, J.J. Canales, J. Burda, R. Planells-Cases, F. Sánchez-Baeza, T. Carbonell, E. Pérez-Payá, A. Messeguer, A. Ferrer-Montiel, and V. Felipo Prevention of in vivo excitotoxicity by a family of trialkylglycines, a novel class of neuroprotectants J. Pharmacol. Exp. Ther. 301 2002 29 36 (Pubitemid 34250276)
25. Y. Nagai, T. Tucker, H. Ren, D.J. Kenan, B.S. Henderson, J.D. Keene, W.J. Strittmatter, and J.R. Burke Inhibition of polyglutamine protein aggregation and cell death by novel peptides identified by phage display screening J. Biol. Chem. 275 2000 10437 10442 (Pubitemid 30202104)
26. Y. Nagai, N. Fujikake, K. Ohno, H. Higashiyama, H.A. Popiel, J. Rahadian, M. Yamaguchi, W.J. Strittmatter, J.R. Burke, and T. Toda Prevention of polyglutamine oligomerization and neurodegeneration by the peptide inhibitor QBP1 in Drosophila Hum. Mol. Genet. 12 2003 1253 1259
27. Y. Nagai, T. Inui, H.A. Popiel, N. Fujikake, K. Hasegawa, Y. Urade, Y. Goto, H. Naiki, and T. Toda A toxic monomeric conformer of the polyglutamine protein Nat. Struct. Mol. Biol. 14 2007 332 340 (Pubitemid 46608340)
28. H.A. Popiel, Y. Nagai, N. Fujikake, and T. Toda Protein transduction domain-mediated delivery of QBP1 suppresses polyglutamine-induced neurodegeneration in vivo Mol. Ther. 15 2007 303 309 (Pubitemid 46111880)
29. H.A. Popiel, Y. Nagai, N. Fujikake, and T. Toda Delivery of the aggregate inhibitor peptide QBP1 into the mouse brain using PTDs and its therapeutic effect on polyglutamine disease mice Neurosci. Lett. 449 2009 87 92
30. M.M. Reddy, R. Wilson, J. Wilson, S. Connell, A. Gocke, L. Hynan, D. German, and T. Kodadek Identification of candidate IgG biomarkers for Alzheimer's disease via combinatorial library screening Cell 144 2011 132 142
31. I. Sánchez, C. Mahlke, and J. Yuan Pivotal role of oligomerization in expanded polyglutamine neurodegenerative disorders Nature 421 2003 373 379 (Pubitemid 36157935)
32. J. Shao, and M.I. Diamond Polyglutamine diseases: emerging concepts in pathogenesis and therapy Hum. Mol. Genet. 16 2007 Spec No. 2, R115-R123
33. R.J. Simon, R.S. Kania, R.N. Zuckermann, V.D. Huebner, D.A. Jewell, S. Banville, S. Ng, L. Wang, S. Rosenberg, and C.K. Marlowe Peptoids: a modular approach to drug discovery Proc. Natl. Acad. Sci. USA 89 1992 9367 9371
34. L.S. Simpson, L. Burdine, A.K. Dutta, A.P. Feranchak, and T. Kodadek Selective toxin sequestrants for the treatment of bacterial infections J. Am. Chem. Soc. 131 2009 5760 5762
35. E.J. Slow, J. van Raamsdonk, D. Rogers, S.H. Coleman, R.K. Graham, Y. Deng, R. Oh, N. Bissada, S.M. Hossain, and Y.Z. Yang Selective striatal neuronal loss in a YAC128 mouse model of Huntington disease Hum. Mol. Genet. 12 2003 1555 1567 (Pubitemid 36857303)
36. G. Stevanin, A. Dürr, and A. Brice Clinical and molecular advances in autosomal dominant cerebellar ataxias: from genotype to phenotype and physiopathology Eur. J. Hum. Genet. 8 2000 4 18 (Pubitemid 30113790)
37. T.S. Tang, E. Slow, V. Lupu, I.G. Stavrovskaya, M. Sugimori, R. Llinás, B.S. Kristal, M.R. Hayden, and I. Bezprozvanny Disturbed Ca2+ signaling and apoptosis of medium spiny neurons in Huntington's disease Proc. Natl. Acad. Sci. USA 102 2005 2602 2607 (Pubitemid 40279423)
38. T.S. Tang, X. Chen, J. Liu, and I. Bezprozvanny Dopaminergic signaling and striatal neurodegeneration in Huntington's disease J. Neurosci. 27 2007 7899 7910 (Pubitemid 47173323)
39. T.S. Tang, C. Guo, H. Wang, X. Chen, and I. Bezprozvanny Neuroprotective effects of inositol 1,4,5-trisphosphate receptor C-terminal fragment in a Huntington's disease mouse model J. Neurosci. 29 2009 1257 1266
40. The Huntington's Disease Collaborative Research Group A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes Cell 72 1993 971 983
41. D.G. Udugamasooriya, S.P. Dineen, R.A. Brekken, and T. Kodadek A peptoid "antibody surrogate" that antagonizes VEGF receptor 2 activity J. Am. Chem. Soc. 130 2008 5744 5752 (Pubitemid 351600507)
42. D.G. Udugamasooriya, G. Dunham, C. Ritchie, R.A. Brekken, and T. Kodadek The pharmacophore of a peptoid VEGF receptor 2 antagonist includes both side chain and main chain residues Bioorg. Med. Chem. Lett. 18 2008 5892 5894
43. J.P. Vonsattel, and M. DiFiglia Huntington disease J. Neuropathol. Exp. Neurol. 57 1998 369 384 (Pubitemid 28237321)
44. J.P. Vonsattel, R.H. Myers, T.J. Stevens, R.J. Ferrante, E.D. Bird, and E.P. Richardson Jr. Neuropathological classification of Huntington's disease J. Neuropathol. Exp. Neurol. 44 1985 559 577 (Pubitemid 16196286)
45. J.L. Wacker, M.H. Zareie, H. Fong, M. Sarikaya, and P.J. Muchowski Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer Nat. Struct. Mol. Biol. 11 2004 1215 1222
46. J. Wang, S. Gines, M.E. MacDonald, and J.F. Gusella Reversal of a full-length mutant huntingtin neuronal cell phenotype by chemical inhibitors of polyglutamine-mediated aggregation BMC Neurosci. 6 2005 1
47. J. Wang, C.E. Wang, A. Orr, S. Tydlacka, S.H. Li, and X.J. Li Impaired ubiquitin-proteasome system activity in the synapses of Huntington's disease mice J. Cell Biol. 180 2008 1177 1189 (Pubitemid 351468473)
48. H. Wang, X. Chen, Y. Li, T.S. Tang, and I. Bezprozvanny Tetrabenazine is neuroprotective in Huntington's disease mice Mol. Neurodegener. 5 2010 18
49. J.M. Warrick, H.Y. Chan, G.L. Gray-Board, Y. Chai, H.L. Paulson, and N.M. Bonini Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 Nat. Genet. 23 1999 425 428
50. W.J. Wolfgang, T.W. Miller, J.M. Webster, J.S. Huston, L.M. Thompson, J.L. Marsh, and A. Messer Suppression of Huntington's disease pathology in Drosophila by human single-chain Fv antibodies Proc. Natl. Acad. Sci. USA 102 2005 11563 11568 (Pubitemid 41153859)
51. J. Wu, T. Tang, and I. Bezprozvanny Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease Neurosci. Lett. 407 2006 219 223 (Pubitemid 44402868)
52. J. Wu, Q. Li, and I. Bezprozvanny Evaluation of Dimebon in cellular model of Huntington's disease Mol. Neurodegener. 3 2008 15
53. J. Wu, H.K. Jeong, S.E. Bulin, S.W. Kwon, J.H. Park, and I. Bezprozvanny Ginsenosides protect striatal neurons in a cellular model of Huntington's disease J. Neurosci. Res. 87 2009 1904 1912
54. J. Wu, H.P. Shih, V. Vigont, L. Hrdlicka, L. Diggins, C. Singh, M. Mahoney, R. Chesworth, G. Shapiro, and O. Zimina Neuronal store-operated calcium entry pathway as a novel therapeutic target for Huntington's disease treatment Chem. Biol. 18 2011 777 793
55. A. Wyttenbach, O. Sauvageot, J. Carmichael, C. Diaz-Latoud, A.P. Arrigo, and D.C. Rubinsztein Heat shock protein 27 prevents cellular polyglutamine toxicity and suppresses the increase of reactive oxygen species caused by huntingtin Hum. Mol. Genet. 11 2002 1137 1151 (Pubitemid 34521094)
56. H. Xia, Q. Mao, S.L. Eliason, S.Q. Harper, I.H. Martins, H.T. Orr, H.L. Paulson, L. Yang, R.M. Kotin, and B.L. Davidson RNAi suppresses polyglutamine-induced neurodegeneration in a model of spinocerebellar ataxia Nat. Med. 10 2004 816 820 (Pubitemid 39070854)
57. X. Xiao, P. Yu, H.S. Lim, D. Sikder, and T. Kodadek A cell-permeable synthetic transcription factor mimic Angew. Chem. Int. Ed. Engl. 46 2007 2865 2868 (Pubitemid 46981286)
58. X. Zhang, D.L. Smith, A.B. Meriin, S. Engemann, D.E. Russel, M. Roark, S.L. Washington, M.M. Maxwell, J.L. Marsh, and L.M. Thompson A potent small molecule inhibits polyglutamine aggregation in Huntington's disease neurons and suppresses neurodegeneration in vivo Proc. Natl. Acad. Sci. USA 102 2005 892 897 (Pubitemid 40282761)
59. R.N. Zuckermann, and T. Kodadek Peptoids as potential therapeutics Curr. Opin. Mol. Ther. 11 2009 299 307